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Registries have greatly contributed to knowledge about PAH epidemiology, risk factors, prognosis and
treatment. Future registries face unique challenges but may benefit from integration of multiple data
sources and capitalising on “Big Data” opportunities. http://bit.ly/2OBpapG
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Disease registries are important sources of real-world evidence that inform clinical practice and health
policy, particularly when randomised controlled trials do not exist [1]. Much of what we know today
about pulmonary arterial hypertension (PAH) has come from observational studies from national and/or
international disease registries.
In this issue of the European Respiratory Review, SWINNEN et al. [2] provide a concise and comprehensive
overview of how various registries have contributed to the current and evolving state of knowledge on
PAH. They illustrate some of the major successes of modern PAH registries, which have broadened our
understanding of changing patient demographics, epidemiology, natural history, risk factors and prognosis
in PAH. Despite their inherent limitations, registry data continue to influence clinical practice and
treatment guidelines. For example, the most recent PAH treatment algorithm in the 2018 World
Symposium on Pulmonary Hypertension [3] proposes a risk-based approach to therapy, based largely on
independent validation of risk assessment strategies from European and US PAH registries [4–8]. Another
example of the influence of registry data on clinical care is the common use of initial triple combination
therapy with an intravenous prostacyclin, an endothelin receptor antagonist and a phosphodiesterase
type 5 inhibitor for patients with high risk PAH, which comes from registry studies showing improved
outcomes in treated patients [9], despite an absence of randomised controlled study data to support this
practice.
Importantly, SWINNEN et al. [2] highlight the differences between current and past PAH registries, and the
methodological limitations inherent to registry-based study designs. However, there are many remaining
questions about PAH that can likely only be addressed in the setting of large patient registries. The
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authors provide insightful perspective on future opportunities for PAH registries in the present era of
“Big Data”. For rare diseases like PAH, there is enormous potential for future registries in terms of larger
numbers of well-characterised patients across the globe with linkage to other data sources, such as health
administrative data or biobanks. Such large scale, multinational initiatives could help us better understand
aspects of PAH such as health resource utilisation in the real-world, geographic or sociocultural gaps in
diagnosis or treatment, or the link between pharmacogenomic differences in populations and long-term
outcomes. Other opportunities include the potential to integrate validated patient-reported data from
mobile devices and digital health data or physical activity tracking apps with PAH registries. The authors
also correctly note that future registries would be more useful if they use common data elements to permit
sharing between countries and organisations, fostering collaboration and multinational research. The
European Respiratory Society has supported several lung disease registries including the PHAROS (severe
Pulmonary Hypertension mAnagement acROSs europe) Clinical Research Collaboration, which was
launched in February 2019 (www.ersnet.org/research/clinical-research-collaborations). PHAROS will
establish a platform for clinical research in pulmonary hypertension, in close collaboration with the
European Reference Network (ERN)-LUNG [10]. During the selection process of the healthcare providers
participating in the ERN-LUNG, essential information about the clinical and scientific expertise and
infrastructure across Europe has been gathered. As part of the ERN-LUNG objectives, an inventory of
existing national and local pulmonary hypertension registries has also been performed and interoperability
to exchange data is under further evaluation. Coordination of existing and future European pulmonary
hypertension registries is one of the key specific aims of PHAROS.
However, with large-scale international registry initiatives, database linkage, integration of patient-level
digital mobile technology and data sharing come serious and legitimate concerns about data ownership
and privacy. Data is now a valuable commodity, equally so for health data. Big Data offers great power,
and with great power comes great responsibility. Recent global events, such as the Cambridge Analytica
scandal, mobile data breaches and patient concerns over data security may further tighten regulations on
sharing medical information to such an extent that future multinational registry initiatives are constrained
to the point of being unfeasible. As clinicians and researchers participating in PAH registries, we have the
dual responsibilities of advancing knowledge with the aim of improving care and outcomes, whilst
ensuring patient privacy and confidentiality of data. The latter may be a major challenge, but one worth
our efforts given the enormous potential of integrating new technologies and data sources into future
PAH registries.
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